Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis

Clinical Therapeutics

Volumn 37, Issue 10, 2015, Pages 2366-2380

  Miller, Aaron E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

efficacy; multiple sclerosis; oral disease modifying therapy; safety; teriflunomide

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; TOLUIDINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MONITORING; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LEUKOCYTE; MONONEUROPATHY; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PREGNANCY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RELAPSE; TREATMENT OUTCOME; ADULT; CHEMICALLY INDUCED; DRUG ADMINISTRATION; FEMALE; HEADACHE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

ADULT; CROTONATES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NAUSEA; PROPORTIONAL HAZARDS MODELS; TOLUIDINES; UNITED STATES;

EID: 84945459109     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.08.003     Document Type: Review

References (22)

1. Aubagio tablets [US prescribing information] 2014 Genzyme Corporation, a Sanofi Company Cambridge, Mass
2. Gilenya (fingolimod) capsules [US prescribing information] 2012 Novartis East Hanover, N J
3. Tecfidera capsules [US prescribing information] 2013 Biogen Idec Inc Cambridge, Mass
4. R. Gold, and J.S. Wolinsky Pathophysiology of multiple sclerosis and the place of teriflunomide Acta Neurol Scand 124 2011 75 84
5. A. Bar-Or, A. Pachner, F. Menguy-Vacheron, and et al. Teriflunomide and its mechanism of action in multiple sclerosis Drugs 74 2013 659 674
6. Arava tablets [US prescribing information] 2012 sanofi-aventis Bridgewater, NJ
7. P. Oconnor, J.S. Wolinsky, C. Confavreux, and et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis New Engl J Med 365 2011 1293 1303
8. P.W. Oconnor, D. Li, M.S. Freedman, and et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 2006 894 900
9. C. Confavreux, P. Oconnor, G. Comi, and et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 247 256
10. A.E. Miller, J.S. Wolinsky, L. Kappos, and et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 977 986
11. C.M. Poser, D.W. Paty, L. Scheinberg, and et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
12. W.I. McDonald, A. Compston, G. Edan, and et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
13. J.S. Wolinsky, P.A. Narayana, F. Nelson, and et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide Mult Scler 19 2013 1310 1319
14. A.E. Miller, P. Oconnor, J.S. Wolinsky, and et al. Pre-specified subgroup analyses of a placebo-controlled Phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis Mult Scler 18 2012 1625 1632
15. C.H. Polman, S.C. Reingold, G. Edan, and et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
16. F. Menguy-Vacheron, J. Msihid, F. Poitiers, and et al. Lack of effect on cardiac repolarisation with teriflunomide compared with placebo: a thorough ECG study Mult Scler 17 Suppl 192 2011 P458
17. M.S. Freedman Teriflunomide in relapsing multiple sclerosis: therapeutic utility Ther Adv Chronic Dis 4 2013 192 205
18. Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. Presented at the Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May-2 June 2012, San Diego, CA. P10.
19. S. Turpault, F. Menguy-Vacheron, and T. Limsakun Evaluation of pharmacokinetics and tolerability of oral teriflunomide in subjects with mild and moderate hepatic impairment Mult Scler 16 2010 P849
20. F. Menguy-Vacheron, P.-F. Clot, L. Cai, and et al. Effect of severe renal impairment on the pharmacokinetics and tolerability of teriflunomide J Neurol 259 Suppl 1 2012 1 236 P463
21. M.S. Freedman, J.S. Wolinsky, B. Wamil, and et al. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial Neurology 78 2012 1877 1885
22. M.S. Freedman, J.S. Wolinsky, B. Wamil, and et al. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis Int J MS Care 13 Suppl 3 2011 P17